Imatinib mesylate (gleevec)-targeted kinases are expressed in uterine sarcomas

Jimmy J. Caudell, Michael T. Deavers, Brian M. Slomovitz, Karen H. Lu, Russell R. Broaddus, David M. Gershenson, Lois M. Ramondetta

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

The purpose of this study was to determine whether 3 tyrosine kinases known to be inhibited by imatinib mesylate are expressed in a variety of uterine sarcomas. The authors assessed c-kit, abl, and platelet-derived growth factor receptor-β (PDGFR-β) expression in 8 endometrial stromal sarcomas (ESSs), 5 leiomyosarcomas (LMSs), 4 high-grade endometrial sarcomas (HGESs), and 21 malignant mixed müllerian tumors (MMMTs). Tissue sections were stained with commercially available antibodies for c-kit, abl, and PDGFR-β. Staining intensity was described as 0 (no staining), +1 (weak), +2 (moderate), and +3 (strong). Positive staining was defined as moderate to strong if found in more than 10% of tumor cells. Expression of c-kit ranged from 0% in LMSs to 25% in HGESs. Protein expression of abl was more significant, ranging from 25% in LMSs and ESSs to 43% in MMMTs. Only 1 LMS sample stained focally for abl (+1). Abl expression was observed in only the carcinomatous elements of the MMMTs, with diffuse staining in the cytoplasm and nucleus. In most, the staining intensity was +2. All tumors stained positive for PDGFR-β. MMMT samples showed PDGFR-β expression in both the carcinomatous and sarcomatous portions. In all samples, staining for PDGFR-β was concentrated at the cell membrane and diffusely in the cytoplasm. These results indicate that many uterine sarcomas express 1 or more of the kinases targeted by imatinib mesylate and that further investigation of imatinib as a therapy for uterine sarcomas is warranted.

Original languageEnglish (US)
Pages (from-to)167-170
Number of pages4
JournalApplied Immunohistochemistry and Molecular Morphology
Volume13
Issue number2
DOIs
StatePublished - Jun 1 2005
Externally publishedYes

Keywords

  • PDGFR-β
  • Tyrosine kinase inhibitor
  • Uterine sarcoma
  • c-kit

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Imatinib mesylate (gleevec)-targeted kinases are expressed in uterine sarcomas'. Together they form a unique fingerprint.

  • Cite this